Table II.
Therapeutic regimens
| Regimen | Number of patients (%) |
|---|---|
| HyperCVAD | 66 (19) |
| HyperCVAD + Rituximab | 75 (22) |
| HyperCVAD + Ofatumumab | 23 (7) |
| HyperCVAD + TKI | |
| Imatinib | 22 (7) |
| Dasatinib | 65 (19) |
| Dasatinib + Rituximab | 15 (4) |
| Ponatinib | 25 (7) |
| Ponatinib + Rituximab | 11 (3) |
| “Mini” HyperCVAD | 2 (0.6) |
| “Mini” HyperCVAD + Rituximab | 22 (7) |
| HyperCMAD | 6 (2) |
| HyperCMAD + Dasatinib | 7 (2) |
| HyperCMAD + Imatinib | 1 (0.3) |
HyperCVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine; TKI, tyrosine kinase inhibitor